The historical rank and industry rank for CanSino Biologics's OCF Margin % or its related term are showing as below:
SHSE:688185'
s OCF Margin % Range Over the Past 10 Years
Min: -10921 Med: -183.08 Max: 46.85
Current: 11.36
During the past 10 years, the highest OCF Margin % of CanSino Biologics was 46.85%. The lowest was -10921.00%. And the median was -183.08%.
SHSE:688185's OCF Margin % is ranked better than 55.47% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs SHSE:688185: 11.36
CanSino Biologics OCF Margin % Related Terms
CanSino Biologics OCF Margin % Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanSino Biologics (SHSE:688185) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CanSino Biologics and its competitors. According to the industry distribution chart, CanSino Biologics ranks #427 out of 959 companies in the Drug Manufacturers industry, placing it in the top 44.5%.
Is CanSino Biologics' OCF Margin % too high?
CanSino Biologics' current OCF Margin % is 0.00%. Based on the distribution chart, CanSino Biologics ranks #427 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CanSino Biologics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #427 out of 959 companies for OCF Margin %. This puts CanSino Biologics in the upper half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (SHSE:688185) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥110.92, compared to a current price of ¥50.03 — trading 54.9% below its estimated fair value. The current OCF Margin % is 0.00%. CanSino Biologics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For CanSino Biologics (SHSE:688185), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (SHSE:688185) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of ¥50.03 is trading 54.9% below its estimated GF Value™ of ¥110.92.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for SHSE:688185:
OCF Margin %: 0.00%
GF Value™: ¥110.92 vs. price of ¥50.03 (54.9% below fair value)
No single metric tells the full story. See the SHSE:688185 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
70GF Score
Get the complete analysis for SHSE:688185
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688185 has been successfully added to your 
